# Seminar 7: Gestational Diabetes and Diabetes in Pregnancy
## Year 3: Obstetrics and Gynecology Clerkship
---
## Learning Objectives
By the end of this seminar, students will be able to:
1. Screen and diagnose gestational diabetes
2. Describe pregestational diabetes management
3. Apply glycemic targets in pregnancy
4. Manage insulin therapy in pregnancy
5. Recognize fetal complications of diabetes
6. Describe peripartum diabetes management
---
## Seminar Outline
### I. Gestational Diabetes Overview
Gestational diabetes mellitus (GDM) is defined as glucose intolerance that is first recognized during pregnancy, excluding women with overt diabetes diagnosed before conception or early in the first trimester. This condition affects approximately 6-9% of pregnancies in the United States, with prevalence continuing to increase in parallel with rising rates of obesity in the general population. GDM represents a significant public health concern due to its associations with both immediate pregnancy complications and long-term health consequences for mothers and their offspring. The diagnosis specifically applies to women without pre-existing type 1 or type 2 diabetes, though the distinction can sometimes be challenging in women presenting for prenatal care without prior glucose testing.
Multiple risk factors have been identified that increase a woman's likelihood of developing gestational diabetes during pregnancy. Obesity with body mass index of 30 or greater represents one of the strongest modifiable risk factors, with risk increasing proportionally with increasing BMI. Prior gestational diabetes in a previous pregnancy is the strongest predictor of recurrence, with rates as high as 50-70% in subsequent pregnancies. A history of delivering a macrosomic infant weighing more than 4000 grams suggests prior undiagnosed or inadequately controlled glucose intolerance. Family history of diabetes mellitus in a first-degree relative, certain ethnicities including Hispanic, African American, Asian, and Pacific Islander, polycystic ovary syndrome, and advanced maternal age of 35 years or greater all contribute to increased risk.
The pathophysiology of gestational diabetes involves the interplay between pregnancy-induced insulin resistance and inadequate pancreatic beta cell compensation. During normal pregnancy, placental hormones including human placental lactogen, progesterone, cortisol, and growth hormone create a state of progressive insulin resistance that begins in the second trimester and increases throughout pregnancy. This physiologic insulin resistance serves to shunt glucose preferentially to the developing fetus while the mother utilizes fatty acids for energy. In women who develop GDM, pancreatic beta cells are unable to increase insulin secretion sufficiently to overcome the insulin resistance, resulting in maternal hyperglycemia. The glucose intolerance typically worsens as pregnancy advances and placental hormone production increases, then resolves postpartum when the placenta is delivered.
The long-term implications of gestational diabetes extend beyond the immediate pregnancy for both mother and child. Women with a history of GDM have approximately 50% risk of developing type 2 diabetes within 10-20 years after the affected pregnancy, making postpartum screening and lifestyle counseling essential. Recurrence of GDM in subsequent pregnancies approaches 70%, and each affected pregnancy further increases the cumulative risk of future type 2 diabetes. Children born to mothers with GDM have increased risk of childhood obesity, metabolic syndrome, and eventual development of type 2 diabetes themselves, demonstrating intergenerational transmission of metabolic risk. Cardiovascular disease risk is also elevated in women with a history of GDM, even in those who do not develop overt diabetes, underscoring the importance of long-term follow-up and preventive care.
Panel A: Gestational diabetes prevalence trends showing increasing rates over recent decades correlated with obesity epidemic. Panel B: Risk factor assessment diagram showing maternal characteristics, obstetric history, and medical history contributing to GDM risk. Panel C: Pathophysiology illustration showing placental hormone production, insulin resistance progression, and beta cell compensation failure. Panel D: Long-term outcomes flowchart for mother showing progression to type 2 diabetes and for offspring showing metabolic risk transmission.
---
### II. Screening and Diagnosis
Universal screening for gestational diabetes is recommended for all pregnant women between 24 and 28 weeks gestation, the time when insulin resistance becomes most pronounced and glucose intolerance is most likely to be detectable. Women with risk factors for undiagnosed pre-existing diabetes should be screened at the first prenatal visit using standard diagnostic criteria for diabetes, with repeat screening at 24-28 weeks if initial testing is normal. The two main approaches to GDM screening and diagnosis are the two-step approach favored by the American College of Obstetricians and Gynecologists and the one-step approach recommended by the International Association of Diabetes and Pregnancy Study Groups. Both approaches have advantages and limitations, and either is acceptable depending on institutional protocols and patient populations.
The two-step approach begins with a 50-gram glucose challenge test (GCT) administered without regard to fasting status, making it more convenient for patients and easier to integrate into routine prenatal visits. One hour after consuming the glucose load, venous plasma glucose is measured, with values of 140 mg/dL or greater (or 130 mg/dL at some institutions using a more sensitive threshold) considered a positive screen requiring confirmatory testing. Women who screen positive proceed to a 100-gram, three-hour oral glucose tolerance test performed after an overnight fast. The diagnosis of GDM requires two or more abnormal values using either the Carpenter-Coustan criteria (fasting 95 or greater, 1-hour 180 or greater, 2-hour 155 or greater, 3-hour 140 or greater mg/dL) or the National Diabetes Data Group criteria (fasting 105 or greater, 1-hour 190 or greater, 2-hour 165 or greater, 3-hour 145 or greater mg/dL).
The one-step approach utilizes a 75-gram, two-hour oral glucose tolerance test performed in the fasting state, eliminating the need for a separate screening test. Diagnosis requires only one abnormal value using the IADPSG criteria: fasting glucose of 92 mg/dL or greater, 1-hour glucose of 180 mg/dL or greater, or 2-hour glucose of 153 mg/dL or greater. This approach identifies more women with mild glucose intolerance who would not meet criteria using the two-step approach, but the clinical significance of treating these milder cases remains debated. The one-step approach is more widely used internationally and is endorsed by the American Diabetes Association, though ACOG continues to recommend the two-step approach for routine screening in the United States.
Early screening at the first prenatal visit should be performed for women at high risk for undiagnosed pre-existing diabetes. Risk factors warranting early screening include prior GDM, known impaired glucose tolerance or impaired fasting glucose, hemoglobin A1c of 5.7% or greater, first-degree relative with diabetes, body mass index of 30 or greater, and history of delivering an infant weighing more than 4000 grams. Early screening can use fasting glucose, random glucose, hemoglobin A1c, or a glucose tolerance test, with diagnostic thresholds the same as for non-pregnant individuals. Women diagnosed with diabetes early in pregnancy likely have pre-existing but previously undiagnosed type 2 diabetes rather than GDM. If early screening is normal, repeat testing should be performed at 24-28 weeks, as GDM may not be detectable until later in pregnancy when insulin resistance increases.
Panel A: Universal screening timeline showing 24-28 week screening with early screening criteria for high-risk women. Panel B: Two-step approach flowchart showing 50g GCT screening followed by 100g 3-hour GTT with diagnostic criteria. Panel C: One-step approach diagram showing 75g 2-hour OGTT with IADPSG diagnostic thresholds. Panel D: Early screening algorithm for high-risk women showing testing options and repeat screening recommendations.
---
### III. Pregestational Diabetes
Pregestational diabetes refers to type 1 or type 2 diabetes mellitus that was present before conception, distinguishing it from gestational diabetes which develops during pregnancy. Type 1 diabetes is characterized by autoimmune destruction of pancreatic beta cells requiring lifelong insulin therapy, while type 2 diabetes involves insulin resistance and relative insulin deficiency that may be managed with lifestyle modifications, oral agents, or insulin depending on disease severity. Both types of pregestational diabetes carry significant risks for pregnancy complications, making preconception counseling and optimization of glycemic control before pregnancy critically important. The goal is to achieve hemoglobin A1c of less than 6.5% before conception, though values less than 7% are acceptable when this can be achieved safely without significant hypoglycemia.
Comprehensive preconception counseling should be provided to all women with diabetes who are considering pregnancy, ideally beginning months before conception to allow time for optimization. Glycemic control should be optimized with a target hemoglobin A1c as close to normal as possible, as elevated A1c at conception is directly correlated with increased risk of congenital anomalies. Folic acid supplementation should be increased to 4 mg daily (compared to 0.4 mg for women without diabetes) due to the increased risk of neural tube defects. Medication review is essential, as several commonly used diabetes medications and medications for comorbidities require discontinuation or substitution before pregnancy. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, commonly used for diabetic nephropathy, must be discontinued due to teratogenicity, and statin therapy should be stopped. Baseline assessment of retinopathy and nephropathy should be performed, as these conditions may worsen during pregnancy.
The teratogenic effects of poorly controlled diabetes are directly related to the severity of hyperglycemia during organogenesis, which occurs primarily during the first 8 weeks after conception when many women may not yet know they are pregnant. Women with hemoglobin A1c less than 7% have a risk of major congenital anomalies near the baseline population rate of 2-3%. As A1c increases, the risk rises progressively, reaching 5-10% with A1c of 7-8%, and potentially exceeding 20-25% with A1c greater than 10%. The most common anomalies associated with diabetic embryopathy include cardiac defects such as ventricular septal defect, transposition of the great arteries, and coarctation of the aorta. Neural tube defects including spina bifida and anencephaly occur at 2-3 times the baseline rate. Caudal regression syndrome, though rare, is considered pathognomonic for diabetic embryopathy and involves hypoplasia of the lower spine and lower extremities.
The White classification, while historical, provides a framework for understanding disease severity and anticipated pregnancy complications in women with pregestational diabetes. Class A1 indicates diet-controlled gestational diabetes, while A2 indicates medication-controlled GDM. Class B through D are based on age of onset and duration of diabetes, with higher classes indicating longer disease duration and earlier onset. Classes F, R, and H indicate the presence of nephropathy, proliferative retinopathy, and ischemic heart disease respectively, representing the most significant risk categories. Women in higher White classes have increased risks of preeclampsia, preterm delivery, cesarean section, and adverse perinatal outcomes. While this classification has largely been replaced by more nuanced risk assessment, it remains useful for communicating relative risk levels.
Panel A: Pregestational diabetes classification comparing type 1 and type 2 characteristics with preconception A1c goals. Panel B: Preconception counseling checklist showing glycemic optimization, medication review, and baseline assessments. Panel C: Teratogenicity risk chart correlating hemoglobin A1c levels with congenital anomaly rates and common defect types. Panel D: White classification system showing classes A1 through H with associated risk factors and anticipated complications.
---
### IV. Glycemic Management
Glycemic targets in pregnancy are more stringent than in the non-pregnant state to minimize fetal exposure to hyperglycemia and reduce associated complications. The fasting glucose target is less than 95 mg/dL, reflecting the importance of overnight and early morning glucose control for fetal well-being. One-hour postprandial glucose targets are less than 140 mg/dL, while two-hour postprandial targets are less than 120 mg/dL; the choice between one-hour and two-hour testing depends on institutional protocols and patient preference. Mean glucose levels should be maintained around 100 mg/dL when possible. These targets must be balanced against the risk of hypoglycemia, which can be dangerous for the mother and may trigger counter-regulatory hormone release that subsequently causes hyperglycemia.
Self-monitoring of blood glucose is essential for achieving glycemic targets and guiding therapy adjustments throughout pregnancy. Women with gestational diabetes typically monitor glucose four times daily, including fasting and after each meal, to identify patterns of hyperglycemia requiring intervention. Women with pregestational diabetes often require more frequent monitoring, four to seven times daily, including pre-meal values to assess insulin dosing and occasionally middle-of-the-night values to detect nocturnal hypoglycemia. Continuous glucose monitoring is increasingly utilized in pregnancy, providing real-time glucose data and trend information that can improve glycemic control, particularly in women with type 1 diabetes prone to glucose variability. CGM data should be reviewed regularly with healthcare providers to optimize insulin dosing and identify patterns requiring intervention.
Medical nutrition therapy represents the cornerstone of GDM management and is effective as sole therapy for approximately 70-85% of women with gestational diabetes. Carbohydrate intake should comprise 33-40% of total calories, with emphasis on complex carbohydrates that have lower glycemic index rather than simple sugars that cause rapid glucose excursions. Meals and snacks should be distributed throughout the day, typically as three moderate-sized meals and two to three snacks, to prevent both hyperglycemia from excessive carbohydrate loads and hypoglycemia from prolonged fasting intervals. An evening snack is particularly important to prevent overnight ketosis, which can occur more readily in pregnancy. Referral to a registered dietitian with expertise in diabetes management during pregnancy is recommended for all women with GDM or pregestational diabetes.
The success of diet therapy varies based on the underlying severity of glucose intolerance and patient adherence to recommendations. Approximately 70-85% of women with GDM can achieve adequate glycemic control with diet and lifestyle modifications alone, without requiring medication. Factors associated with failure of diet therapy and need for medication include higher fasting glucose at diagnosis, earlier gestational age at diagnosis, obesity, and history of GDM in previous pregnancy. Women with pregestational diabetes almost universally require insulin therapy, as diet alone is insufficient to overcome the combination of baseline insulin deficiency or resistance plus pregnancy-induced insulin resistance. Monitoring glucose patterns over one to two weeks while implementing diet therapy helps identify women who will require medication, with persistent elevated fasting glucose being a particularly strong predictor of need for insulin.
Panel A: Glycemic targets comparison showing fasting and postprandial goals with timing of measurements. Panel B: Self-monitoring schedule for GDM versus pregestational diabetes with frequency and timing of glucose checks. Panel C: Medical nutrition therapy principles showing carbohydrate distribution, meal planning, and food choices. Panel D: Diet therapy outcomes showing success rates for GDM and factors predicting need for medication escalation.
---
### V. Insulin Therapy
Insulin therapy is indicated when diet and lifestyle modifications fail to achieve glycemic targets in women with gestational diabetes, and it is typically required from the outset for women with pregestational diabetes. The decision to initiate insulin in GDM is based on glucose monitoring data showing persistent elevation above targets despite adherence to nutrition therapy, typically defined as fasting glucose consistently exceeding 95 mg/dL or postprandial values exceeding 140 mg/dL at one hour or 120 mg/dL at two hours. Early initiation of insulin when indicated is important, as even short periods of hyperglycemia during critical developmental periods can contribute to fetal overgrowth and other complications. Most women accept insulin therapy when counseled about its safety and efficacy, though the need for injections can be challenging for some patients.
Multiple insulin formulations are available with varying onset, peak, and duration of action, allowing for tailored regimens based on glucose patterns. Rapid-acting insulin analogs including lispro and aspart have onset of 15 minutes, peak action at 1-2 hours, and duration of 3-5 hours, making them ideal for postprandial glucose control when dosed with meals. Regular insulin has slightly slower onset at 30 minutes, peaks at 2-4 hours, and lasts 6-8 hours. Intermediate-acting NPH insulin has onset of 1-2 hours, pronounced peak at 4-8 hours, and duration of 12-18 hours, providing basal coverage with a peak that can be timed to cover meals when given appropriately. Long-acting insulin analogs including glargine and detemir have onset of 1-2 hours, minimal peak, and duration approaching 24 hours, providing steady basal insulin coverage throughout the day and night.
Common insulin regimens in pregnancy include basal-bolus therapy and split-mixed regimens, with the choice depending on glucose patterns and patient lifestyle. Basal-bolus therapy involves a long-acting insulin for basal coverage plus rapid-acting insulin dosed with each meal, providing flexible coverage that can be adjusted to variable meal timing and composition. Split-mixed regimens combine NPH and rapid-acting insulin given twice daily (before breakfast and before dinner), providing coverage with fewer injections but less flexibility. Initial dosing typically starts at 0.7-1.0 units per kilogram of current body weight per day, divided between basal and bolus components. Insulin requirements increase as pregnancy progresses due to increasing insulin resistance, often requiring dose increases of 50-100% between diagnosis and delivery.
Oral hypoglycemic agents have been used as alternatives to insulin in some settings, though insulin remains the preferred medication for most guidelines. Metformin is used increasingly in GDM and can be effective for glucose control, though it crosses the placenta and long-term effects on offspring are not fully characterized. Glyburide was previously used widely but has fallen out of favor due to concerns about higher rates of macrosomia and neonatal hypoglycemia compared to insulin. ACOG and ADA consider metformin an acceptable alternative when patients refuse insulin or have significant barriers to insulin therapy, but recommend counseling about the placental transfer and limited long-term safety data. Insulin does not cross the placenta and has the longest safety record in pregnancy, making it the preferred pharmacologic agent when medication is required.
Panel A: Indications for insulin initiation showing glucose thresholds and timing of decision-making in GDM. Panel B: Insulin formulations chart comparing rapid-acting, short-acting, intermediate, and long-acting insulins with pharmacokinetic profiles. Panel C: Insulin regimen diagrams showing basal-bolus and split-mixed approaches with dosing timing. Panel D: Oral agent comparison showing metformin and glyburide with efficacy data, placental transfer, and guideline recommendations.
---
### VI. Fetal Complications
Macrosomia, defined as birth weight exceeding 4000 grams (or 4500 grams by some definitions), represents the most common fetal complication of diabetes in pregnancy and results from the effects of maternal hyperglycemia on fetal metabolism. According to the Pedersen hypothesis, maternal hyperglycemia leads to fetal hyperglycemia across the placenta, which stimulates fetal pancreatic beta cells to produce excess insulin. Fetal hyperinsulinemia acts as a growth factor, promoting excessive deposition of adipose tissue, particularly in insulin-sensitive areas including the trunk, shoulders, and abdomen. This pattern of overgrowth differs from constitutional macrosomia in non-diabetic pregnancies, creating a disproportionate body habitus that increases the risk of shoulder dystocia during vaginal delivery even at similar birth weights. The risk of macrosomia is directly proportional to the degree of maternal glucose control, with even modest elevations in glucose increasing risk.
Congenital anomalies occur at increased rates in pregnancies complicated by pregestational diabetes, with the risk directly related to glycemic control during the first trimester organogenesis period. Gestational diabetes, which develops after the first trimester when organogenesis is largely complete, does not carry increased risk of congenital anomalies. Cardiac malformations are the most common category, occurring in approximately 4% of infants of diabetic mothers compared to 1% in the general population; specific defects include ventricular septal defect, transposition of the great arteries, truncus arteriosus, and coarctation of the aorta. Neural tube defects including spina bifida and anencephaly occur at 2-3 times the baseline rate. Caudal regression syndrome, though rare (affecting 1 in 350 infants of diabetic mothers compared to 1 in 100,000 in the general population), is strongly associated with maternal diabetes and involves varying degrees of sacral and lower extremity hypoplasia.
Additional fetal complications of diabetic pregnancy include polyhydramnios, increased risk of preterm birth, and stillbirth. Polyhydramnios (excessive amniotic fluid) results from fetal polyuria secondary to fetal hyperglycemia and osmotic diuresis, and it increases the risk of preterm labor, umbilical cord prolapse, and placental abruption. Preterm birth rates are increased both spontaneously (due to polyhydramnios and increased uterine distension) and iatrogenically (due to maternal complications requiring early delivery). Stillbirth risk is elevated in diabetic pregnancies, particularly in women with poor glycemic control or vascular complications; the mechanism may involve chronic fetal hypoxia from placental dysfunction or acute metabolic derangement. Paradoxically, intrauterine growth restriction can occur in women with diabetic vascular disease affecting uterine blood flow, representing a different phenotype than the more common macrosomic pattern.
Neonatal complications in infants of diabetic mothers are common and require anticipation and monitoring after delivery. Neonatal hypoglycemia is the most frequent complication, occurring because the fetal pancreas has been chronically stimulated by maternal hyperglycemia to produce excess insulin, and this hyperinsulinemic state persists after delivery when the maternal glucose supply is suddenly discontinued. Hyperbilirubinemia requiring phototherapy is more common, related to polycythemia (elevated red blood cell mass from chronic fetal hypoxia) and increased red cell turnover. Respiratory distress syndrome can occur even in late preterm or term infants because fetal hyperinsulinemia delays pulmonary surfactant production. Hypocalcemia and hypomagnesemia occur through mechanisms that are not fully understood but may relate to maternal hyperglycemia affecting fetal parathyroid function.
Panel A: Macrosomia pathophysiology diagram showing Pedersen hypothesis with maternal hyperglycemia, fetal hyperinsulinemia, and characteristic growth pattern. Panel B: Congenital anomalies chart showing cardiac, neural tube, and caudal regression defects with prevalence rates. Panel C: Other fetal complications including polyhydramnios mechanism, preterm birth, and stillbirth risk factors. Panel D: Neonatal complications flowchart showing hypoglycemia, hyperbilirubinemia, respiratory distress, and electrolyte abnormalities with mechanisms and management.
---
### VII. Antepartum Monitoring
Ultrasound surveillance in diabetic pregnancies serves multiple purposes including confirming dating, assessing fetal anatomy, and monitoring fetal growth throughout pregnancy. First-trimester ultrasound confirms gestational age, which is essential for accurate interpretation of subsequent growth assessments and appropriate timing of delivery decisions. The anatomy ultrasound at 18-22 weeks should include detailed evaluation of cardiac structures given the increased risk of congenital heart defects; fetal echocardiography may be indicated for women with pregestational diabetes or significantly elevated hemoglobin A1c. Third-trimester growth ultrasounds assess for macrosomia or growth restriction, with serial examinations every 4-6 weeks recommended for women requiring medication for glucose control. Estimated fetal weight approaching or exceeding 4500 grams influences delivery planning and counseling regarding mode of delivery.
Antenatal fetal testing is recommended for diabetic pregnancies to detect fetal compromise before irreversible injury or stillbirth occurs. The timing of initiation and frequency of testing depends on disease severity and glucose control. Women with diet-controlled gestational diabetes who maintain excellent glycemic control may not require routine antenatal testing, though some providers recommend testing beginning at 36-40 weeks. Women with medication-controlled GDM or any pregestational diabetes typically begin testing at 32 weeks gestation, with weekly or twice-weekly non-stress tests or biophysical profiles. More frequent testing (twice weekly or even daily) may be indicated for women with poor glycemic control, vascular complications, or other high-risk factors. Abnormal test results require prompt evaluation and may indicate need for delivery.
Fetal kick counting provides a simple method of fetal surveillance that engages patients in monitoring their pregnancy between formal testing appointments. Patients are instructed to count fetal movements beginning at 28 weeks gestation, typically after meals when fetal activity tends to be greatest. A normal result is perception of 10 distinct fetal movements within 2 hours, though most women will achieve this in much less time. Decreased fetal movement should prompt contact with the healthcare provider for formal evaluation with non-stress test or biophysical profile. While evidence supporting kick counting as a standalone surveillance strategy is limited, it serves as an important supplement to formal testing and may prompt earlier evaluation of fetal status in some cases.
Ultrasound findings in diabetic pregnancy can provide important information about glucose control and anticipated complications. Macrosomia with estimated fetal weight above the 90th percentile or absolute weight above 4000 grams suggests inadequate glycemic control and increased risk of birth trauma with vaginal delivery. Polyhydramnios with amniotic fluid index exceeding 24 cm or single deepest pocket exceeding 8 cm may indicate poor glucose control with resultant fetal polyuria, and it increases the risk of umbilical cord prolapse and malpresentation. Estimated fetal weight exceeding 4500 grams prompts discussion of cesarean delivery to avoid shoulder dystocia. Serial growth assessments demonstrating progressive macrosomia despite intensive management may prompt earlier delivery to prevent excessive fetal size at the time of delivery.
Panel A: Ultrasound surveillance schedule showing first trimester dating, anatomy survey timing, fetal echo indications, and growth monitoring frequency. Panel B: Antenatal testing protocol comparing diet-controlled GDM, medication-controlled GDM, and pregestational diabetes with testing initiation and frequency. Panel C: Fetal kick counting instructions showing timing, technique, and action thresholds for decreased movement. Panel D: Ultrasound findings interpretation showing macrosomia thresholds, polyhydramnios criteria, and management implications.
---
### VIII. Delivery Planning
The timing of delivery in diabetic pregnancies balances the risks of continued pregnancy (stillbirth, worsening macrosomia, birth trauma) against the risks of early delivery (neonatal morbidity from prematurity). Women with diet-controlled gestational diabetes who maintain excellent glycemic control can be managed expectantly until 40 weeks and 6 days gestation, similar to low-risk pregnancies, though delivery should not extend beyond 41 weeks. Gestational diabetes requiring medication for glucose control warrants delivery between 39 weeks 0 days and 39 weeks 6 days to minimize the risk of stillbirth while avoiding unnecessary prematurity. Pregestational diabetes with good glycemic control and no vascular complications can similarly be delivered at 39 weeks 0 days to 39 weeks 6 days. Poorly controlled diabetes, vascular complications, or other pregnancy complications may warrant earlier delivery between 37 and 39 weeks, individualized based on specific clinical circumstances.
The mode of delivery in diabetic pregnancies is determined by standard obstetric indications, with additional consideration given to estimated fetal weight due to the increased risk of shoulder dystocia. Vaginal delivery is appropriate and encouraged when estimated fetal weight is below 4500 grams and no other contraindications exist, as cesarean delivery carries its own significant risks and complications. When estimated fetal weight is between 4500 and 5000 grams in a diabetic pregnancy, the increased risk of shoulder dystocia warrants discussion of cesarean delivery, though vaginal delivery is not absolutely contraindicated. Estimated fetal weight exceeding 5000 grams in a diabetic pregnancy is considered an indication for cesarean delivery due to the very high risk of shoulder dystocia and permanent brachial plexus injury. A history of shoulder dystocia in a prior delivery, particularly if it resulted in permanent injury, should prompt serious consideration of cesarean delivery regardless of current estimated fetal weight.
Intrapartum glucose management aims to maintain maternal euglycemia during labor and delivery to minimize the risk of neonatal hypoglycemia. Target glucose levels during labor are 70-110 mg/dL, tighter than antepartum targets because even modest hyperglycemia shortly before delivery can stimulate fetal insulin secretion and worsen neonatal hypoglycemia. Glucose monitoring should occur hourly during active labor to guide insulin and dextrose administration. Women with gestational diabetes typically do not require insulin during labor and may have normal glucose levels without intervention. Women with pregestational diabetes require careful insulin management, often with significant reduction in their usual doses as caloric intake decreases during labor; an intravenous insulin drip with concurrent dextrose infusion provides the most precise control.
Anesthesia considerations in diabetic parturients include the general principles applicable to all patients plus specific attention to diabetes-related comorbidities. Regional anesthesia with epidural or combined spinal-epidural provides excellent pain control and is safe in diabetic patients without contraindications. Glucose monitoring should continue during regional anesthesia, as insulin sensitivity may change and glucose levels should be maintained within target range. Women with pregestational diabetes and autonomic neuropathy may have altered cardiovascular responses to regional anesthesia, though this is uncommon. For cesarean delivery, regional anesthesia is preferred over general anesthesia when feasible. Adequate glucose control should be maintained throughout the procedure and into the recovery period.
Panel A: Delivery timing algorithm by diabetes type and control status showing gestational age recommendations for diet-controlled GDM, medication-controlled GDM, and pregestational diabetes. Panel B: Mode of delivery decision tree based on estimated fetal weight thresholds and shoulder dystocia risk. Panel C: Intrapartum glucose protocol showing target range, monitoring frequency, and insulin/dextrose management. Panel D: Anesthesia considerations including regional anesthesia technique, glucose monitoring during procedures, and autonomic neuropathy assessment.
---
### IX. Postpartum Management
Postpartum glucose management differs substantially depending on whether the patient had gestational diabetes or pregestational diabetes. Women with gestational diabetes typically experience normalization of glucose immediately after delivery once the placenta is removed and insulin resistance resolves; insulin therapy should be discontinued immediately postpartum and glucose monitored briefly to confirm resolution. Women with type 1 diabetes will continue to require insulin but at substantially reduced doses, typically 50% of their pre-pregnancy requirements initially, due to the sudden decrease in insulin resistance. Women with type 2 diabetes may resume oral agents postpartum or may transition back to insulin at reduced doses depending on their pre-pregnancy regimen and current glucose levels. Glucose monitoring should continue for 24-72 hours postpartum to ensure appropriate adjustment of therapy.
Postpartum screening for persistent glucose intolerance is essential for women who had gestational diabetes, as many will have or will develop type 2 diabetes. Screening should be performed at 4-12 weeks postpartum, after the immediate postpartum period but before the 6-week postpartum visit to allow time for intervention if abnormalities are detected. The recommended test is a 75-gram, 2-hour oral glucose tolerance test, using standard non-pregnant diagnostic criteria (fasting glucose 126 or greater, 2-hour glucose 200 or greater indicates diabetes; fasting 100-125 or 2-hour 140-199 indicates prediabetes). If postpartum testing is normal, screening should be repeated every 1-3 years indefinitely, as the cumulative risk of developing type 2 diabetes continues to increase over time. Women diagnosed with prediabetes should receive counseling about lifestyle modifications and may be candidates for metformin therapy for diabetes prevention.
Breastfeeding provides important benefits for both mother and infant in diabetic pregnancies and should be encouraged and supported. For the mother, breastfeeding improves glucose tolerance and may reduce the long-term risk of developing type 2 diabetes after GDM. For the infant, breastfeeding may reduce the risk of childhood obesity and metabolic complications associated with being born to a diabetic mother. Glucose levels may fluctuate during breastfeeding, and women on insulin should be counseled to have rapid-acting carbohydrates available to treat hypoglycemia during or after nursing. Most diabetes medications are compatible with breastfeeding, including metformin and insulin. Caloric intake should be adequate to support lactation while maintaining appropriate glucose control.
Contraception counseling should be provided to all women with diabetes before discharge, emphasizing the importance of pregnancy planning and preconception care for future pregnancies. The goal is to ensure that any subsequent pregnancy occurs with optimized glycemic control to minimize the risk of congenital anomalies and pregnancy complications. All contraceptive methods are acceptable for women with diabetes, including hormonal methods, intrauterine devices, and barrier methods; the choice should be individualized based on patient preferences and medical considerations. Long-acting reversible contraceptives (IUDs and implants) are particularly appropriate for women who desire highly effective contraception while optimizing their health before future pregnancy. Women should be counseled that preconception care with target hemoglobin A1c less than 6.5% is associated with significantly better pregnancy outcomes.
Panel A: Immediate postpartum glucose management showing insulin discontinuation for GDM, dose reduction for type 1, and transition planning for type 2. Panel B: Postpartum screening protocol showing timing, test selection, diagnostic criteria, and follow-up surveillance schedule. Panel C: Breastfeeding benefits and considerations including maternal and infant benefits, hypoglycemia management, and medication compatibility. Panel D: Contraception counseling framework emphasizing pregnancy planning, preconception A1c goals, and method options.
---
### X. Special Considerations
Diabetic ketoacidosis (DKA) in pregnancy represents a medical emergency with potential for significant maternal and fetal morbidity and mortality. DKA occurs almost exclusively in women with type 1 diabetes but can occasionally occur in type 2 diabetes with significant insulin deficiency. Importantly, "euglycemic DKA" can occur in pregnancy at lower glucose thresholds than in non-pregnant patients (glucose may be 200-300 mg/dL rather than the typical greater than 400 mg/dL), making diagnosis more challenging. Precipitating factors include infection, missed insulin doses, beta-agonist tocolysis, corticosteroid administration, and insulin pump malfunction. Fetal mortality rates historically exceeded 50% with DKA, though contemporary management has improved outcomes. Treatment involves aggressive intravenous fluid resuscitation, continuous insulin infusion, electrolyte replacement (particularly potassium), and identification and treatment of precipitating causes. Fetal heart rate monitoring often shows abnormalities during DKA that typically improve with maternal treatment; delivery should generally be deferred until maternal stabilization unless fetal status fails to improve.
Hypoglycemia is a significant concern in pregnant women with diabetes, particularly those with type 1 diabetes on intensive insulin therapy. Pregnancy alters the counter-regulatory hormone response to hypoglycemia and may blunt hypoglycemia awareness, putting women at risk for severe episodes. Hypoglycemia risk is highest during the first trimester when insulin sensitivity is increased and nausea may limit caloric intake. Symptoms of hypoglycemia may be attenuated, and women should be educated about atypical warning signs. Treatment involves consumption of 15-20 grams of rapid-acting carbohydrate, with blood glucose rechecked after 15 minutes and treatment repeated if needed. Glucagon emergency kits should be prescribed for women at risk of severe hypoglycemia, and household members should be instructed in their use. Recurrent hypoglycemia warrants review of insulin doses, meal timing, and glucose monitoring practices.
Diabetic retinopathy requires careful attention during pregnancy, as the condition may progress during pregnancy even in women with previously stable eye disease. All women with pregestational diabetes should have a comprehensive dilated eye examination before pregnancy or early in the first trimester to establish baseline status. Repeat examinations should be performed each trimester for women with any degree of retinopathy, or more frequently if progression is noted. Factors associated with progression include poor glycemic control, rapid improvement in glycemic control (which paradoxically can temporarily worsen retinopathy), longer duration of diabetes, and presence of hypertension. Laser photocoagulation can be performed safely during pregnancy if needed to treat proliferative retinopathy or clinically significant macular edema. Retinopathy typically stabilizes or improves after delivery, though women with significant progression during pregnancy require close postpartum follow-up.
Diabetic nephropathy complicates a minority of diabetic pregnancies but is associated with significant maternal and fetal risks when present. Assessment before pregnancy should include serum creatinine and 24-hour urine collection for protein and creatinine clearance to establish baseline renal function. Women with nephropathy have increased risks of preeclampsia (which can be difficult to distinguish from worsening nephropathy), preterm delivery, and intrauterine growth restriction from vascular insufficiency. Proteinuria typically increases during pregnancy due to increased glomerular filtration rate but may not indicate true disease progression. Blood pressure control is particularly important, though angiotensin-converting enzyme inhibitors and angiotensin receptor blockers must be discontinued due to teratogenicity, requiring substitution with other antihypertensive agents. Women with significant renal impairment (creatinine greater than 1.5 mg/dL or creatinine clearance less than 50 mL/min) have increased risk of further renal deterioration during pregnancy and should receive thorough counseling about these risks.
Panel A: Diabetic ketoacidosis in pregnancy showing precipitating factors, euglycemic presentation, treatment protocol, and fetal monitoring considerations. Panel B: Hypoglycemia management including risk factors, recognition of atypical symptoms, treatment algorithm, and glucagon emergency kit instructions. Panel C: Diabetic retinopathy surveillance showing examination schedule, progression risk factors, and indications for laser treatment during pregnancy. Panel D: Diabetic nephropathy assessment and management including baseline evaluation, distinguishing from preeclampsia, and medication considerations.
---
## Summary
- GDM screening is universal at 24-28 weeks; use 50g GCT followed by 100g 3-hour GTT (two-step) or 75g 2-hour OGTT with single abnormal value (one-step)
- GDM diagnostic criteria (two-step, Carpenter-Coustan): fasting 95 or greater, 1-hour 180 or greater, 2-hour 155 or greater, 3-hour 140 or greater mg/dL; requires two or more abnormal values
- Glycemic targets: fasting less than 95 mg/dL, 1-hour postprandial less than 140 mg/dL, 2-hour postprandial less than 120 mg/dL
- Diet therapy alone controls 70-85% of GDM; 3 meals plus 2-3 snacks with 33-40% carbohydrates
- Insulin is preferred pharmacotherapy when medication is needed; basal-bolus regimen with rapid-acting for meals and long-acting for basal coverage
- Macrosomia results from maternal hyperglycemia causing fetal hyperinsulinemia (Pedersen hypothesis), leading to excessive adipose deposition
- Congenital anomalies (cardiac, neural tube, caudal regression) relate to first-trimester A1c in pregestational diabetes only
- Delivery timing: 39-39+6 weeks for medication-controlled GDM and well-controlled pregestational diabetes; expectant management to 40+6 weeks for diet-controlled GDM
- Postpartum GTT at 4-12 weeks for GDM; if normal, repeat every 1-3 years due to 50% lifetime risk of type 2 diabetes
- DKA in pregnancy may occur at lower glucose levels (euglycemic DKA); fetal mortality is high without prompt treatment
---
## Key Terms
| Term | Definition |
|------|------------|
| Gestational diabetes | Glucose intolerance first recognized during pregnancy, excluding pre-existing diabetes |
| Macrosomia | Birth weight exceeding 4000 grams (or 4500 grams by some definitions) |
| Glucose challenge test | 50-gram non-fasting screening test for gestational diabetes |
| Glucose tolerance test | 75-gram or 100-gram diagnostic test for diabetes performed in fasting state |
| Pedersen hypothesis | Maternal hyperglycemia leads to fetal hyperglycemia and hyperinsulinemia, causing macrosomia |
| Euglycemic DKA | Diabetic ketoacidosis occurring at lower glucose levels than typical, more common in pregnancy |
| White classification | Historical classification system for diabetes in pregnancy based on disease duration and complications |
| Shoulder dystocia | Impaction of fetal shoulders during vaginal delivery, associated with macrosomia |
---
*This content is subject to the [MIT License](https://opensource.org/licenses/MIT). © 2024–2026 Hibbert School of Medicine.*